Last updated: 5 months ago
InflaRx N.V. Report: Phase 2a Study for INF904 Dosing Begins!
InflaRx N.V. announces the first dosing in its Phase 2a study for INF904, targeting CSU and HS. Results expected in summer 2025. Key insights and strategies unveiled.